Indian drugmakers likely to stay competitive despite planned tariffs, Dr Reddy's says

Feb 25 (Reuters) - Indian drugmakers are likely to remain competitive in the generic drugs market in the face of U.S. President Donald Trump's plans to levy tariffs on pharmaceutical imports, Dr Reddy's Managing Director GV Prasad said on Tuesday.

The Indian pharmaceutical industry is still waiting for more clarity on any tariffs before taking any action given a lack of details, Prasad said on the sidelines of the BioAsia conference in the Southern Indian state of Telangana. The tariffs would likely raise costs for U.S. consumers or middlemen, he added.

"In reality, to shift all these products from worldwide into the United States is not practical. They don't have that much capacity, and their costs will rise. Even with tariffs, I think Indian and Chinese companies would be competitive."